Antofagasta PLC

Antofagasta and Barrick Gold JV wins $5.84bn in damages over Pakistan's Reko Diq dispute

The pair's 50:50 joint venture Tethyan Copper had filed an arbitration claim in 2011 after it was denied a mining lease for one of the largest undeveloped copper and gold deposits in the world

Shares in Antofagasta were up 4.5% to 901.73p in early trade on Monday.

Antofagasta PLC (LON:ANTO) and Barrick Gold Corp (TSE:ABX) have been awarded US$5.84bn in damages after seven years of arbitration over the disputed Reko Diq project in Pakistan.  

The government of Pakistan will have to pay the damages to Tethyan Copper, a 50:50 joint venture between Antofagasta and Barrick after the amount was decided by an international arbitration tribunal of the World Bank's International Centre for Settlement of Investment Disputes (ICSID).

"We remain willing to discuss the potential for a negotiated settlement with Pakistan and will continue to protect our commercial interests and legal rights until the conclusion of this dispute," said Tethyan Copper chairman William Hayes.

Tethyan Copper filed an arbitration claim over what it felt was an unlawful denial of a mining lease for Reko Diq in 2011 by the provincial government of Balochistan, which a feasibility study had indicated was one of the largest undeveloped copper and gold deposits in the world.

Compensation of US$4.1bn was decided with reference to the fair market value of Reko Diq at the time the mining lease was denied, plus interest of US$1.75bn and just under US$62mln of legal costs.

There are limited grounds for challenging the award under the ICSID convention. 

Antofagasta said it did not expect to recognise the damages payment in its financial statements until the money had been received.

Shares in Antofagasta were up 4.5% to 901.73p in early trade on Monday.

Quick facts: Antofagasta PLC

Price: £8.10

Market: LSE
Market Cap: £79.97 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

6 hours, 8 minutes ago

2 min read